167 related articles for article (PubMed ID: 27380460)
1. Older Patients With Hepatocellular Carcinoma Have More Advanced Disease, Lower Rates of Treatment, and Lower Survival.
Yan M; Ha J; Aguilar M; Liu B; Frenette CT; Bhuket T; Wong RJ
J Clin Gastroenterol; 2017 Apr; 51(4):378-383. PubMed ID: 27380460
[TBL] [Abstract][Full Text] [Related]
2. Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival.
Yan M; Ha J; Aguilar M; Bhuket T; Liu B; Gish RG; Cheung R; Wong RJ
J Hepatol; 2016 Feb; 64(2):326-332. PubMed ID: 26386160
[TBL] [Abstract][Full Text] [Related]
3. Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment.
Wang J; Ha J; Lopez A; Bhuket T; Liu B; Wong RJ
J Clin Gastroenterol; 2018; 52(5):437-443. PubMed ID: 28723861
[TBL] [Abstract][Full Text] [Related]
4. Association of socioeconomics, surgical therapy, and survival of early stage hepatocellular carcinoma.
Peters NA; Javed AA; He J; Wolfgang CL; Weiss MJ
J Surg Res; 2017 Apr; 210():253-260. PubMed ID: 28457336
[TBL] [Abstract][Full Text] [Related]
5. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.
Ha J; Yan M; Aguilar M; Bhuket T; Tana MM; Liu B; Gish RG; Wong RJ
Cancer; 2016 Aug; 122(16):2512-23. PubMed ID: 27195481
[TBL] [Abstract][Full Text] [Related]
6. Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies.
Ha J; Yan M; Aguilar M; Tana M; Liu B; Frenette CT; Bhuket T; Wong RJ
J Clin Gastroenterol; 2016; 50(5):423-30. PubMed ID: 26583267
[TBL] [Abstract][Full Text] [Related]
7. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
9. Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era.
Devaki P; Wong RJ; Marupakula V; Nangia S; Nguyen L; Ditah IC; Ehrinpreis MN; Nguyen MH
Cancer; 2014 Jun; 120(11):1725-32. PubMed ID: 24590359
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
[TBL] [Abstract][Full Text] [Related]
11. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.
El-Serag HB; Davila JA
Hepatology; 2004 Mar; 39(3):798-803. PubMed ID: 14999699
[TBL] [Abstract][Full Text] [Related]
12. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
14. Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score.
Wong RJ; Devaki P; Nguyen L; Cheung R; Cho-Phan C; Nguyen MH
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1534-40.e1. PubMed ID: 24361414
[TBL] [Abstract][Full Text] [Related]
15. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.
Rich NE; Hester C; Odewole M; Murphy CC; Parikh ND; Marrero JA; Yopp AC; Singal AG
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):551-559.e1. PubMed ID: 29859983
[TBL] [Abstract][Full Text] [Related]
16. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria.
Takuma Y; Nouso K; Makino Y; Gotoh T; Toshikuni N; Morimoto Y; Shimomura H; Yamamoto H
J Gastroenterol Hepatol; 2011 Sep; 26(9):1417-24. PubMed ID: 21884248
[TBL] [Abstract][Full Text] [Related]
17. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
[TBL] [Abstract][Full Text] [Related]
18. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.
Serper M; Taddei TH; Mehta R; D'Addeo K; Dai F; Aytaman A; Baytarian M; Fox R; Hunt K; Goldberg DS; Valderrama A; Kaplan DE;
Gastroenterology; 2017 Jun; 152(8):1954-1964. PubMed ID: 28283421
[TBL] [Abstract][Full Text] [Related]
19. Natural history and treatment trends in hepatocellular carcinoma subtypes: Insights from a national cancer registry.
Jernigan PL; Wima K; Hanseman DJ; Hoehn RS; Ahmad SA; Shah SA; Abbott DE
J Surg Oncol; 2015 Dec; 112(8):872-6. PubMed ID: 26603598
[TBL] [Abstract][Full Text] [Related]
20. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
